Mutually beneficial relationship between Sandoz and Pear Therapeutics highlights the value of a digital therapeutics partnership

July 02, 2019 | Case Study

As Lux continues to recommend that clients engage with digital therapeutics, it is important to consider how to assess digital therapeutics companies as partnership or investment opportunities, especially in terms of how they are navigating the current healthcare landscape. One of the ways digital therapeutics companies are doing this is through partnership with pharmaceutical companies. Here, we highlight Pear Therapeutics' partnership with Sandoz, the generic arm of Novartis. Through this partnership, Sandoz is adopting a strategy to demonstrate an effort toward mitigating some of the negative impacts of the abuse of some opioid products using Pear Therapeutics' reSET and reSET-O products. In turn, Sandoz is negotiating reimbursement with payers and subsidizing some of the use of the product to in order to drive physician adoption, gaining the longitudinal data necessary to drive broader insurance payer reimbursement.

About Lux Research

Lux Research is a leading provider of tech-enabled research and advisory solutions, helping clients drive growth through technology innovation. A pioneer in the research industry, Lux uniquely combines technical expertise and business insights with a proprietary intelligence platform, using advanced analytics and data science to surface true leading indicators. With quality data derived from primary research, fact-based analysis, and opinions that challenge traditional thinking, Lux clients are empowered to make more informed decisions today to ensure future success.

Already a Lux Client?

Sign In

Interested in Learning More?

Contact us to learn the benefits of becoming a Lux member.

Or call us now

For North America (Boston Headquarters)
+1 (617) 502-5300

For EMEA (Amsterdam)
+31 20 280 7900

For APAC (Singapore)
+65 6592-6978